This course is FREE with Unlimited CE!

Choose from two Unlimited CE subscription options and get access to 750+ CE and professional development courses.

Goal and Learning Outcomes

The goal of this course is to provide evidence-based recommendations to nursing professionals in acute care settings regarding sedation management, central line-associated bloodstream infections (CLABSIs), and early enteral feeding to prevent malnutrition.
After taking this course, you should be able to:
  • Describe the nurse’s role during a spontaneous awakening and spontaneous breathing trial in the mechanically ventilated, critically ill patient population.
  • Identify the nurse’s role in decreasing the risk of central line-associated bloodstream infections (CLABSIs).
  • Discuss at least three characteristics of malnutrition and current recommendations for early initiation of enteral feedings in critically ill patients.

Course Authors

4.7 Average

Course Reviews

897 reviews

Accreditation Information


In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791



Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses


Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.



None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.